The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors. The main questions it aims to answer are: • Does hydrocortisone replacement therapy reduce the incidence of adrenal insufficiency in participants? Researchers will compare hydrocortisone to a placebo (a look-alike substance that contains no drug) to see if hydrocortisone works to reduce the incidence of adrenal insufficiency. Participants will: * Take or intravenous infusion drug hydrocortisone or a placebo every day for 2 weeks * Visit the clinic three months after surgery for checkups and tests * Keep a diary of their symptoms
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
882
Perioperative Hydrocortisone Reduction Therapy
Perioperative placebo Reduction Therapy
Beijing, Beijing Tiantan Hospital,Capital Medical University
Beijing, Beijing Municipality, China
RECRUITINGThe incidence of adrenal insufficiency on the first or second day after surgery
Time frame: the first or second day after surgery
The incidence of adrenal insufficiency within 90 days after surgery
Time frame: Within 90 days after surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.